Lv11
20 积分 2024-09-18 加入
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study
14天前
已完结
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia
24天前
已完结
Targeting TP53 disruption in chronic lymphocytic leukemia: Current strategies and future directions
2个月前
已完结
Chronic lymphocytic leukaemia
2个月前
已完结
皖公网安备34019202002308
